Hungary authorises use of US drugmaker Lilly’s Covid-19 antibody drug
Hungary has become the first European country to grant authorisation to the emergency use of US drugmaker Eli Lilly’s Covid-19 antibody drug bamlanivimab, the human resources ministry said on Wednesday.
The National Institute of Pharmacy and Nutrition (OGYEI) earlier this month approved the use of bamlanivimab for the treatment of patients with mild and moderate cases of Covid-19 who are at risk of developing more serious forms of the disease, the ministry said in a statement.
Bamlanivimab antibody therapy can minimise complications resulting from coronavirus and help patients avoid hospitalisation, thereby also easing the pressure on doctors, nurses and the hospital system as a whole, it added.
Patients will be administered the drug in designated hospital centres, the ministry said, adding that the cost of the treatment would be fully covered by the government.
Hungarian coronavirus patients could have access to the treatment as early as the second half of January, it said, adding that Hungary will receive thousands of ampoules of bamlanivimab in the first quarter of next year.
Bamlanivimab is the first monoclonal antibody therapy to have been granted authorisation in the United States and Canada.
- Read more news about CORONAVIRUS IN HUNGARY
![sputnik_v_hungary_vaccine_coronavirus](https://contentf5.dailynewshungary.com/wp-content/uploads/2020/11/sputnik-V-hungary-vaccine-2020-russia.jpg)
Read alsoChief epidemiologist calls for Hungarians’ trust in vaccinations
Source: MTI
please make a donation here
Hot news
What happened today in Hungary – 26 July, 2024
Drama: number of births in a 20-year low in Hungary
Yay or nay? – 6 odd Hungarian delicacies that make our skin crawl
Budapest tourism “exploded” this past weekend
Container transport in Budapest may stop: How will this affect Hungarian economy?
Minister: Hungary will protect its territory by every means possible